Curated News
By: NewsRamp Editorial Staff
December 03, 2025
Sigyn's CardioDialysis™ Targets 20-Fold Higher Heart Risk in Dialysis Patients
TLDR
- Sigyn Therapeutics' CardioDialysis offers a competitive edge by targeting a $100 billion market with a broad-spectrum therapy that reduces MACE more effectively than single-target drugs.
- CardioDialysis works by reducing inflammatory molecules and cholesterol-transporting lipoproteins during dialysis treatments, leveraging existing dialysis machine infrastructure for deployment.
- This therapy could significantly improve and extend the lives of ESRD patients by addressing their unique cardiovascular risks during regular dialysis sessions.
- CardioDialysis transforms kidney dialysis clinics into cardiovascular treatment centers using existing equipment to combat a leading cause of death worldwide.
Impact - Why it Matters
This development matters because cardiovascular disease represents the leading cause of death for end-stage renal disease patients, who face dramatically higher mortality rates than the general population despite regular dialysis treatments. Current pharmaceutical approaches have proven ineffective for this vulnerable group, creating an urgent unmet medical need affecting approximately 550,000 ESRD patients in the U.S. alone who undergo 85 million dialysis treatments annually. CardioDialysis™ offers a novel approach that could potentially extend patient survival beyond the current 3-5 year median while addressing the systemic inflammation that dialysis treatments themselves can exacerbate. The technology's ability to leverage existing dialysis infrastructure makes it potentially scalable and accessible, unlike current specialized apheresis treatments available at fewer than 60 centers nationwide. Beyond patient health benefits, successful implementation could transform the economics of dialysis care by reducing hospitalizations and creating new revenue streams in a $100+ billion cardiovascular therapy market.
Summary
Sigyn Therapeutics, a medical technology company developing dialysis-like therapies, has announced that its CardioDialysis™ technology aligns with recent scientific findings published in Nature regarding the urgent need to address cardiovascular disease in end-stage renal disease (ESRD) patients. The company's CEO, Jim Joyce, highlighted that a Nature review article confirmed ESRD dialysis patients face up to a 20-fold greater risk of cardiovascular death compared to the general population, and that existing cardiovascular drugs have failed to improve survival in this vulnerable group. This reinforces Sigyn's focus on CardioDialysis™, which aims to tackle dialysis-induced inflammation and cholesterol-transporting lipoproteins during regular dialysis sessions.
CardioDialysis™ represents a breakthrough medical device approach that diverges from traditional pharmaceutical strategies by targeting multiple inflammatory pathways simultaneously rather than single molecules. The technology leverages the existing global infrastructure of dialysis machines, with approximately 150,000 machines already deployed in U.S. clinics alone, potentially transforming kidney dialysis centers into combined renal and cardiovascular treatment facilities. This approach addresses the unique challenges faced by ESRD patients, who typically survive only 3-5 years after becoming dialysis-dependent and receive limited benefit from standard cholesterol-lowering statins.
The potential impact of CardioDialysis™ extends beyond patient health to significant economic implications for the dialysis industry, dominated by companies like DaVita and Fresenius Medical Care. By reducing hospitalizations and extending patient lives, the technology could help recapture up to $654 million in weekly lost revenues and potentially add $2.8 billion in monthly revenues to the U.S. dialysis industry. Furthermore, CardioDialysis™ builds upon the proven concept of Lipoprotein Apheresis, which has demonstrated 59-95% reductions in Major Adverse Cardiovascular Events (MACE), significantly outperforming pharmaceutical statins that typically achieve only 20-45% reductions. The company's broader pipeline includes additional therapies for cancer treatment optimization, positioning Sigyn Therapeutics at the forefront of innovative blood purification technologies for life-threatening conditions.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn's CardioDialysis™ Targets 20-Fold Higher Heart Risk in Dialysis Patients
